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SELECTION OF THE MONTH 
Big Title: MRI may replace invasive portal pressure measurements 
Small titles: The global HCV genotype distribution in PWIDs 
Can Dromedary camel HEV be transmitted to humans? 
 
CELL TRANSPLANTATION 
Thalidomide: an old drug for a new indication? 
Cell transplantation has been proposed as an alternative to liver transplantation. 
However, efficient engraftment of transplanted cells is critical. Engraftment failure may 
be related to recruitment of neutrophils or Kupffer cells. Thalidomide is a drug which 
can reduce recruitment of these cells by inhibiting cytokine production and/or signaling. 
Here using an elegant animal model, Viswanathan et al. show that thalidomide 
improves transplanted cell engraftment and liver repopulation. Thalidomide 
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effects were not fully recapitulated by repertaxin or etanercept suggesting an original 
mechanism of action. 
 
HEPATOCELLULAR ADENOMA (HCA) 
Post-menopausal follow-up 
Hepatocellular adenoma (HCA) is a rare benign liver tumor which develops in women 
in their reproductive phase and is associated with the use of oral contraceptives. It is 
uncertain whether or not follow-up should be terminated after the occurrence of 
menopause in women with HCA. Klompenhouwer et al. addressed this question in a 
cross-sectional cohort study in 48 post-menopausal women with HCA. They show 
important data: first, HCA-diameter becomes significantly smaller after the occurrence 
of menopause and as time progresses this regression increases, suggesting that 
routine follow-up of HCA <5cm in post-menopausal women is not required. 
Second, they show found that patient's mental health-related quality of life was inferior 
to that of the general population.   
 
HEPATOCELLULAR CARCINOMA (HCC) 
Effectiveness of surveillance for HCC 
Little is known on the effectiveness of surveillance for HCC in reducing cancer-
related mortality among patients with cirrhosis. Mittal et al. conducted a retrospective 
cohort study of patients with HCC during 2005-2010 by reviewing patients' medical 
records to determine receipt of HCC surveillance in the 2 years prior to HCC 
diagnosis. They now provide important results showing that among patients with 
HCC, pre diagnosis HCC surveillance is associated with a significant 38% 
reduction in overall mortality. The reduction in mortality risk with surveillance is 
mediated via stage migration and receipt of HCC specific treatment. 
 
NON-ALCOHOLIC STEATOHEPATITIS (NAFLD) 
BCL3 mediates inflammation in NASH, autophagy Related Gene IRGM 
variations and risk for NAFLD, mechanisms of malnutrition-associated liver 
steatosis 
The B-cell CLL/lymphoma 3 (BCL3) gene product regulates NFκB - a key inducer of 
inflammation -. In this issue, Gehrke et al. investigated the role of this gene in 
experimental and human NAFLD. Hepatocyte-specific overexpression of Bcl3 led 
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to hepatic steatosis, augmented inflammatory milieu and hepatocellular injury. 
Moreover, Bcl-3 expression decreased insulin sensitivity. The authors identified the 
transcription factors PPARα, PPARγ and PGC-1α as critical regulators of hepatic 
metabolism and inflammation downstream of Bcl-3. Remarkably, these findings were 
recapitulated in human NASH, which exhibited increased expression and 
nuclear localization of BCL-3. This study reveals a role for BCL3 as a novel 
regulator of steatosis, insulin sensitivity and inflammation in NASH. 
Autophagy regulates lipid stores in hepatocytes. Ni et al. studied whether the gene 
called immunity-related GTPase family M (IRGM) - an autophagy-related gene -  
variants confer the susceptibility to NAFLD. A total of 832 obese children and 
adolescents were recruited and NAFLD was determined by liver ultrasonography. 
Twenty-three percent of the obese children and adolescents had NAFLD. After 
controlling for age- and gender-adjusted body mass index, gender, PNPLA3 and 
TM6SF2 polymorphisms, a variant in IRGM rs10065172 ([TT] genotype) 
independently increased the odds ratio of NAFLD by 2. In vitro studies revealed 
that IRGM regulates autophagic flux and lipid droplet content in hepatocytes. This 
interesting study suggests that IRGM may contribute to the development of human 
NAFLD by altering hepatic lipid metabolism through the autophagy pathway. 
Severe malnutrition is associated with steatosis and hypoalbuminemia, but its 
etiology is largely unknown. Van Zutphen et al. investigates the role of peroxisomes 
and mitochondria in a rat model of malnutrition. Low protein diet-fed rats developed 
hypoalbuminemia and hepatic steatosis, associated with peroxisomal dysfunction. 
This was followed by structural and functional changes in mitochondria and 
reduced hepatic ATP levels. Interestingly, fenofibrate restored hepatic peroxisome 
abundance and increased mitochondrial β-oxidation, resulting in reduced steatosis 
and normalization of ATP and plasma albumin levels. This study shows novel 
mechanisms of malnutrition-induced liver dysfunction and proposes a protective 
effect by fibrates. 
 
HEPATITIS C VIRUS (HCV) INFECTION  
The global HCV genotype distribution in PWIDs, at the EDGE – Head-2-Head 
comparison of IFNa-free with IFNa-containing DAA regimens, decline in 
hepatocellular carcinoma trends among Australian people with HBV but not with 
HCV infection 
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People who inject drugs (PWID) are a high risk population for transmitting HCV that 
contributes significantly to the current spreading of the virus, and most likely will 
influence the future global burden of the HCV epidemiology. So far, there exists no 
systematic review on the HCV genotype distribution in PWID. The knowledge thereof, 
however, is relevant as the HCV genotype still determines treatment response, disease 
progression as well as vaccine development strategies. The study by Robaeys et al. is 
the first to investigate the distribution of the HCV genotypes in PWID globally, and 
compares the results with the distribution of HCV genotypes in the general population 
(see Gower et. al., J Hepatol 2014; 61 (Suppl 1): S45-57). The most important 
differences comparing with the general population are a lower prevalence of 
HCV genotype 1b in the PWID population and higher prevalence of genotype 1a 
and 3. The study also provides evidence that HCV type 3 has spread from India over 
Afghanistan into Europe, and further across the oceans to North and South America 
and Australia due to the opiate drug trafficking routes. 
The HCV treatment revolution started early in 2014 when the EMA licensed sofosbuvir 
in combination with peginterferon (IFNa) plus ribavirin as a pangenotypic regimen 
leading to robust cure rates of 90%. Although, direct acting antiviral (DAA) regimens 
with an IFNa backbone have now been replaced by IFNa-free DAA combinations, it 
has never been studied so far whether the latter regimens, although less cumbersome, 
are also more efficacious as compared to the former one. The C-EDGE Head-2-Head 
phase III study by Sperl et al. is the first addressing this issue by randomizing HCV 
type 1-, and 4-infected patients to either a once-daily oral fixed-dose combination of 
elbasvir plus grazoprevir (EBR/GZR) or sofosbuvir plus pegIFNa and ribavirin 
(SOF/PR) for 12 weeks. Overall, EBR/GZR showed superior efficacy and safety in 
the treatment of patients with HCV type 1 or 4 infection compared with SOF/PR. 
For all those who might still had doubts, these findings can be considered as proof 
that IFNa is now finally buried.  
Chronic hepatitis B virus (HBV) and HCV infections are the major causes of 
hepatocellular carcinoma (HCC), responsible for around 80% of cases worldwide. 
Although long-term follow-up studies clearly suggest that effective antiviral treatment 
reduces the individual HCC risk, there are limited data how our previous antiviral 
treatment strategies affected the population-based HCC burden. The study by Waziry 
et al. evaluated HCC trends among people with HBV or HCV infection in New South 
Wales, Australia between 2000 and 2014. Whereas the population-level burden of 
5 
 
new HCC cases per year has stabilized in the HBV cohort, it increased markedly 
in the HCV cohort. Also the age-standardised incidence rates of HCC significantly 
declined among those with HBV and remained stable in those with HCV. This elegant 
study provides clear evidence for a population-based declining HBV-associated HCC 
risk as a result of improving HBV antiviral therapy in the mid-2000s. In contrast, the 
interferon-containing HCV treatment era had no impact on individual-level HCV-related 
HCC risk in Australia. 
 
HEPATITIS E VIRUS (HEV) INFECTION 
Can Dromedary camel HEV be transmitted to humans? 
In humans, at least four HEV genotypes exist, and whereas genotypes 1 and 2 have 
been exclusively found in humans, HEV types 3 and 4 have been also isolated from 
animals, including monkeys, domestic pigs, wild boars, wild deer, and mongooses, and 
are responsible for zoonotic HEV transmission. More recently, a Dromedary camel 
HEV (DcHEV) was identified, and classified as HEV genotype 7. The serotype of 
DcHEV was similar to those of HEV type 1 and 3; however, there was neither a cell 
culture system to grow the virus nor evidence whether DcHEV was capable of being 
transmitted from camels to humans. Li et al. used a reverse genetic system to produce 
infectious DcHEV from cloned cDNA which grew well in PLC/PRF/5 cells, and were 
able to infect Cynomolgus monkeys. Moreover, the antigenicity and immunogenicity of 
DcHEV were similar to those of G1, G3 and G4 HEV. This important study 
demonstrates that DcHEV has the potential to cause a cross-species zoonotic 
HEV infection in primates and might be therefore - in theory - also capable of being 
transmitted from camels to humans. 
 
PORTAL HYPERTENSION 
Novel application of MRI provides information on portal pressure 
At present, the treatment of portal hypertension is seriously limited by the need to 
perform invasive portal pressure measurements, which requires special skill, is 
invasive and cumbersome to use in clinical practice routinely. An important paper in 
the present issue of the Journal by Palaniyappan et al. describes very convincing 
data suggesting that using novel algorithms to calculate splanchnic 
hemodynamics and hepatic architectural characteristics very closely reflects 
invasive measurements of hepatic venous pressure gradient. This model was 
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then validated in a small cohort. If the data generated in this paper can be reproduced 
accurately, it may be a game changer for the practicing Hepatologist. 
 
HEPATIC ENCEPHALOPATHY 
CSF metabolomics 
Treatment approaches to hepatic encephalopathy are limited by the lack of information 
about the metabolic derangements in the brain of patients. Detailed analysis of the 
cerebrospinal fluid (CSF) has been lacking due to limited technology in the past and 
availability of CSF samples. In an important paper, Weiss et al. address this issue in 
detail for the first time. They studied patients with hepatic encephalopathy and healthy 
volunteers and performed metabolomics analyses of the CSF and plasma. Their data 
clearly show evidence of blood-brain gradient of many metabolites, most 
notable amongst which are metabolites associated with alterations in energy 
metabolism and the brain exposure to bile acids was also enormous. These data 
provide novel insights and possibly novel approaches to treatment.  
 
NEONATAL SCLEROSING CHOLANGITIS (NSC) 
NSC is a novel liver-based ciliopathy 
NSC is a devastating clinical condition characterized by severe cholangiopathy, rapid 
progression to end stage cirrhosis and need for liver transplantation. The mechanisms 
underlying this disease are unclear. Grammatikopoulos et al. provide novel data about 
the genetic basis of NSC. They performed whole exome sequencing and identified 
that NSC patients harbor mutations in DCDC2, which encodes for doublecortin 
domain containing 2 and is expressed in cholangiocyte cilia. The data identify 
NSC as a novel liver-based ciliopathy. Further studies of DCDC2 function are likely to 
provide insights into cholangiocyte biology and function. 
 
